Lantern Pharma launches ZetaOmics cancer bioinformatics tool
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
July 8, 2026 7:30 AM EDTFirst previewed in the companys May roadmap, the new withZeta.ai module now enters early access with leading bioinformatics teams and Lantern collaborators autonomously designing experiments, building rigorous cohorts from 615,000+ curated cancer samples, and delivering publication-ready multi-omic analysis in minutes
A new class of research agent. ZetaOmics is an autonomous Computational Biologist that goes beyond automating software it reasons about experimental design, prevents pitfalls that produce false discoveries, and makes statistically rigorous decisions on its own, encoding the judgment of a tenured bioinformatician so that scientific rigor is the default across rare and common cancers... More